NeuroOne’s CEO Talks About 510(k) Clearance Of Evo sEEG Electrodes
Executive Summary
Medtech Insight spoke to Dave Rosa, CEO of NeuroOne, about working with the FDA to get a 510(k) clearance.
You may also be interested in...
Minute Insight: NeuroOne Moves Forward With Brain Electrode 510(k) Submission
The company has submitted a 510(k) request for its OneRF Ablation System, which will repurpose previously implanted electrodes into a tool for brain tissue removal.
Minute Insight: NeuroOne Amends Deal With Zimmer Biomet To Shore Up Balance Sheet
Zimmer Biomet agreed to amend its exclusive development and distribution agreement with NeuroOne to pay $3.5m for 350,000 of stock. The deal will help NeuroOne continue to develop its Evo stereoelectroencephalography brain-mapping electrodes without further diluting the company’s stock.
NeuroOne: Thinner Is Better When It Comes To Brain Electrodes
NeuroOne manufactures the thinnest FDA-approved stereoelectroencephalography electrode for 30-day use, and a recent Emory University study could further expand their applications.